Biotech Values

[DonShimoda]

My understanding from yesterday's call is that worldwide about 25% of CML pts are considered high risk while in the US it's about 10% (i'm not sure what accounts for the difference). If ariad pursues first line in high risk pts, this does raise an interesting issue regarding their proposed strategy of keeping the US rights and partnering what could arguably be a much larger opportunity.